Synthesis and biological evaluation of pyridazinone derivatives as potential anti-inflammatory agents. 2018

Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
Université de Reims Champagne-Ardenne, Institut de Chimie Moléculaire de Reims (ICMR), UMR CNRS 7312, UFR Sciences, Moulin de La Housse and UFR Pharmacie, 51 Rue Cognacq-Jay, 51096 Reims, France.

Cyclic nucleotide phosphodiesterase type 4 (PDE4), that controls intracellular level of cyclic nucleotide cAMP, has aroused scientific attention as a suitable target for anti-inflammatory therapy in respiratory diseases. Here we describe the development of two families of pyridazinone derivatives as potential PDE4 inhibitors and their evaluation as anti-inflammatory agents. Among these derivatives, 4,5-dihydropyridazinone representatives possess promising activity, selectivity towards PDE4 isoenzymes and are able to reduce IL-8 production by human primary polymorphonuclear cells.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D009504 Neutrophils Granular leukocytes having a nucleus with three to five lobes connected by slender threads of chromatin, and cytoplasm containing fine inconspicuous granules and stainable by neutral dyes. LE Cells,Leukocytes, Polymorphonuclear,Polymorphonuclear Leukocytes,Polymorphonuclear Neutrophils,Neutrophil Band Cells,Band Cell, Neutrophil,Cell, LE,LE Cell,Leukocyte, Polymorphonuclear,Neutrophil,Neutrophil Band Cell,Neutrophil, Polymorphonuclear,Polymorphonuclear Leukocyte,Polymorphonuclear Neutrophil
D011724 Pyridazines Six-membered rings with two adjacent nitrogen atoms also called 1,2-diazine.
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000894 Anti-Inflammatory Agents, Non-Steroidal Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Analgesics, Anti-Inflammatory,Aspirin-Like Agent,Aspirin-Like Agents,NSAID,Non-Steroidal Anti-Inflammatory Agent,Non-Steroidal Anti-Inflammatory Agents,Nonsteroidal Anti-Inflammatory Agent,Anti Inflammatory Agents, Nonsteroidal,Antiinflammatory Agents, Non Steroidal,Antiinflammatory Agents, Nonsteroidal,NSAIDs,Nonsteroidal Anti-Inflammatory Agents,Agent, Aspirin-Like,Agent, Non-Steroidal Anti-Inflammatory,Agent, Nonsteroidal Anti-Inflammatory,Anti-Inflammatory Agent, Non-Steroidal,Anti-Inflammatory Agent, Nonsteroidal,Anti-Inflammatory Analgesics,Aspirin Like Agent,Aspirin Like Agents,Non Steroidal Anti Inflammatory Agent,Non Steroidal Anti Inflammatory Agents,Nonsteroidal Anti Inflammatory Agent,Nonsteroidal Anti Inflammatory Agents,Nonsteroidal Antiinflammatory Agents
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D054703 Cyclic Nucleotide Phosphodiesterases, Type 4 A cyclic nucleotide phosphodiesterase subfamily that is found predominantly in inflammatory cells and may play a role in the regulation of CELL-MEDIATED IMMUNITY. The enzyme family includes over twenty different variants that occur due to multiple ALTERNATIVE SPLICING of the mRNA of at least four different genes. Cyclic Nucleotide Phosphodiesterase PDE4 Family,Cyclic Nucleotide Phosphodiesterases, Type 4A,Cyclic Nucleotide Phosphodiesterases, Type 4A5,Cyclic Nucleotide Phosphodiesterases, Type 4B,Cyclic Nucleotide Phosphodiesterases, Type 4C,Cyclic Nucleotide Phosphodiesterases, Type 4D,Cyclic Nucleotide Phosphodiesterases, Type 4D3,PDE4 Phosphodiesterases,PDE4D3 Phosphodiesterase,Phosphodiesterase 4,Phosphodiesterase 4A,Phosphodiesterase 4B,Phosphodiesterase 4C,Phosphodiesterase 4D,Phosphodiesterase IV,Phosphodiesterase-4,Type 4 Cyclic Nucleotide Phosphodiesterase,cAMP-Specific Phosphodiesterase 4A5,Phosphodiesterase 4A5, cAMP-Specific,Phosphodiesterase, PDE4D3,Phosphodiesterases, PDE4,cAMP Specific Phosphodiesterase 4A5
D058988 Phosphodiesterase 4 Inhibitors Compounds that specifically inhibit PHOSPHODIESTERASE 4. PDE-4 Inhibitor,PDE4 Inhibitor,Phosphodiesterase 4 Inhibitor,Phosphodiesterase Type 4 Inhibitor,PDE-4 Inhibitors,PDE4 Inhibitors,Phosphodiesterase Type 4 Inhibitors,4 Inhibitor, Phosphodiesterase,Inhibitor, PDE-4,Inhibitor, PDE4,Inhibitor, Phosphodiesterase 4,Inhibitors, PDE-4,Inhibitors, PDE4,Inhibitors, Phosphodiesterase 4,PDE 4 Inhibitor,PDE 4 Inhibitors

Related Publications

Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
April 2021, RSC medicinal chemistry,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
June 2019, European journal of medicinal chemistry,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
January 2017, Iranian journal of pharmaceutical research : IJPR,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
June 2013, European journal of medicinal chemistry,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
January 2009, Bioorganic & medicinal chemistry letters,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
January 2017, Current pharmaceutical design,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
February 2012, Journal of enzyme inhibition and medicinal chemistry,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
September 2014, Fitoterapia,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
November 2016, Bioorganic & medicinal chemistry letters,
Chantal Barberot, and Aurélie Moniot, and Ingrid Allart-Simon, and Laurette Malleret, and Tatiana Yegorova, and Marie Laronze-Cochard, and Abderrazzaq Bentaher, and Maurice Médebielle, and Jean-Philippe Bouillon, and Eric Hénon, and Janos Sapi, and Frédéric Velard, and Stéphane Gérard
March 2004, Bioorganic & medicinal chemistry,
Copied contents to your clipboard!